We want to assure you that we process your personal data in accordance with the GDPR.
Related Posts
Nordic Nanovector has entered into a research and development collaboration programme with Paul Scherrer Institute (PSI) in Switzerland. The collaboration aims at developing new antibody radionuclide conjugates (ARCs) optimised for the treatment of single cell leukaemias, such as chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). CLL and AML…
Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk…
A Working Lab Innomedicum is a new meeting place for life science innovation in Campus Solna at Karolinska Institutet. Akademiska Hus, KI Innovations and KI Science Park have initiated the almost 5 000 squaremeter large co-working environment at Nanna Svartz väg 4 in Solna. It includes flexible workplaces, private offices,…
Nanologica has signed a Services Agreement with GSK to apply its expertise in nanoporous materials and customized drug delivery systems to advance the development of new technology platforms for early stage development projects. ”We are excited about the collaboration with GSK. This is an early, but interesting project with the possibility to unlock…